Healthcare
Compugen Ltd(CGEN)
Live Price
Offline$2.01
+1.01% today
1Y Change
+17.75%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $260.00M
- Revenue Growth
- +161.1%
- EPS Growth
- +337.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Compugen Ltd (CGEN) is a Healthcare stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $2.01 and up 17.8% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of +161.1%, EPS growth of +337.5%, a dividend yield of 0.0%. What stands out right now is revenue +161.1%, EPS +337.5%, free cash flow -36.7% with operating margin 43.1% and ROIC 23.2%. Valuation is more restrained than many high-expectation growth names at P/E 7.3 and price/sales 3.5. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines CGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+161.1% vs +7.6% peer median
Operating Margin
Above sector median
+43.1% vs +19.4% peer median
P/E
Below sector median
7.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 18, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +161.1% and EPS at +337.5%, with operating margin around 43.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 18, 2026 | β | -4.5% | -7.3% | -29.0% |
2026 Mar 2, 2026 | +957.1% | -11.1% | -4.4% | -11.6% |
2025 Nov 10, 2025 | +22.2% | +3.0% | -4.8% | -1.2% |
Benchmark Edge
CGEN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CGEN
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CGEN Max Drawdown
-36.77%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CGEN and SPY.
Company Overview
Compugen Ltd
NASDAQ
Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML. It utilizes its proprietary Unigenβ’ platform, a predictive AI/ML-powered computational discovery tool, to identify novel drug targets and biological pathways for developing immuno-oncology therapies. The company advances wholly owned clinical programs such as COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody in Phase 1 for platinum-resistant ovarian cancer and maintenance therapy in relapsed cases, and COM902, an Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 for solid tumors. Compugen also maintains partnered programs, including bispecific antibodies with AstraZeneca featuring the TIGIT component from COM902, and GS-0321 (formerly COM503), a high-affinity anti-IL-18 binding protein antibody licensed to Gilead for Phase 1 development in advanced solid malignancies. Its pipeline extends to early-stage immuno-oncology research programs targeting new mechanisms to activate the immune system against cancer and overcome resistance. Founded in Israel and headquartered there with offices in San Francisco, California, Compugen Ltd. plays a key role in advancing differentiated antibody therapies in the oncology sector.
- Leadership
- Dr. Eran Ophir Ph.D.
- Employees
- 75
- Street Address
- Azrieli Center, Building D 26 Harokmim Street
- Mailing
- Holon, 5885849
- Region
- Holon, Israel
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 7.3
- EV/EBITDA
- 5.1
- Price/Sales
- 3.5
- Price/Book
- 2.5
Growth
- Revenue
- +161.1%
- EPS
- +337.5%
- Free Cash Flow
- -36.7%
Profitability
- Gross Margin
- 87.3%
- Operating Margin
- 43.1%
- Net Margin
- 48.6%
- ROE
- 55.7%
- ROIC
- 23.2%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 6.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.